Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an announcement.
Alligator Bioscience has secured a U.S. patent covering its proprietary tetravalent bispecific antibody format, which enables dual antigen binding and supports stable, efficient assembly of complex antibody constructs. The protected architecture is designed to power next-generation immunotherapies targeting immune modulators and tumor-associated antigens across a variety of oncology indications and combination strategies.
The newly granted patent underpins multiple internal programs and follows an evaluation and option agreement signed in 2025 for the company’s RUBY antibody format, underscoring external commercial interest in its antibody engineering capabilities. The strengthened intellectual property base bolsters Alligator’s strategy to create long-term value from its antibody platforms both in its own pipeline and through partnerships, reinforcing its competitive position in immuno-oncology.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company specializing in clinical-stage, tumor-directed antibody drugs, with a focus on the CD40 receptor as a validated immuno-oncology target. Its lead candidate, mitazalimab, is ready for Phase 3 development and has shown strong survival data in metastatic pancreatic cancer, positioning the company within the advanced cancer immunotherapy segment.
Average Trading Volume: 4,696,874
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK98.67M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.